New publication shows decisiondx®-scc identifies high-risk squamous cell carcinoma patients who are likely to benefit from adjuvant radiation therapy and those who can consider deferring treatment based on biological risk of metastasis

Friendswood, texas--(business wire)---- $cstl #cstl--castle announced the publication of a study demonstrating the impact of the decisiondx-scc test in guiding adjuvant radiation therapy decision-making.

CSTL Ratings Summary

CSTL Quant Ranking